Micafungin

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Oropharyngeal Candidiasis

Conditions

Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis

Trial Timeline

Oct 14, 2007 → Sep 8, 2011

NCT ID

NCT00608335

About Micafungin

Micafungin is a phase 1 stage product being developed by Astellas Pharma for Oropharyngeal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00608335. Target conditions include Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03174457	Pre-clinical	Completed	Jun 21, 2017	May 31, 2018	Invasive Fungal Infections
NCT03102658	Approved	Completed	Jan 1, 2017	Jul 1, 2017	Morbid Obesity
NCT02440178	Phase 2	Completed	Sep 19, 2015	Jun 1, 2017	Acute Leukemia
NCT03421002	Phase 2	Completed	May 30, 2015	Apr 10, 2018	Candidiasis, Systemic
NCT02678598	Pre-clinical	Completed	Mar 1, 2015	Aug 1, 2015	Invasive Fungal Infections
NCT02127788	Pre-clinical	Completed	Jul 3, 2014	Jan 27, 2016	Antifungal Prophylaxis
NCT02646800	Approved	Terminated	Mar 21, 2014	Dec 21, 2014	Aspergillosis
NCT02646774	Approved	Terminated	Mar 1, 2014	Jun 26, 2015	Invasive Aspergillosis
NCT02057289	Phase 1	Terminated	Jan 1, 2014	Nov 1, 2014	Immunocompromised
NCT01982071	Approved	Terminated	Sep 26, 2013	Aug 28, 2015	Candidemia
NCT01135589	Approved	UNKNOWN	Apr 1, 2010	May 1, 2012	Neutropenia
NCT00606268	Phase 1	Completed	Nov 1, 2007	Mar 1, 2009	Fungal Infections
NCT00608335	Phase 1	Completed	Oct 14, 2007	Sep 8, 2011	Oropharyngeal Candidiasis
NCT00818584	Phase 1	Completed	Aug 1, 2007	Oct 1, 2007	Candida
NCT00842504	Phase 1	Completed	Jul 1, 2007	Dec 1, 2009	Fungal Infection

Competing Products

12 competing products in Oropharyngeal Candidiasis

See all competitors

Product	Company	Stage	Hype Score
Cetuximab + Cisplatin	Eli Lilly	Phase 2	52
Durvalumab + Tremelimumab	AstraZeneca	Phase 1/2	41
Cisplatin + Durvalumab + Tremelimumab	AstraZeneca	Phase 2	52
Cisplatin + Durvalumab	AstraZeneca	Phase 3	77
Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm	AstraZeneca	Phase 2	52
MEDI0457 + Durvalumab	AstraZeneca	Phase 2	52
VB10.16 + Pembrolizumab	Merck	Phase 1/2	41
Cetuximab	Merck	Phase 2	52
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)	Merck	Phase 3	77
Paclitaxel + Carboplatin + Nivolumab	Bristol Myers Squibb	Phase 2	51
Cyclophosphamide + IRX-2 + Nivolumab	Bristol Myers Squibb	Phase 1	32
CUE-101	Cue Biopharma	Phase 2	44

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved